NCT04161391 2024-06-13
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
Turning Point Therapeutics, Inc.
Phase 1/2 Terminated
Turning Point Therapeutics, Inc.
H. Lee Moffitt Cancer Center and Research Institute
University of Wisconsin, Madison
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Institutes of Health Clinical Center (CC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins